Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Known castration-resistant disease~* Serum PSA ≥2 ng/mL (μg/L)~* Multiple skeletal metastases (≥2 hot spots) on bone scan~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2.~* Life expectancy ≥6 months~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* History of visceral metastasis, or visceral metastases~* Malignant lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter~* Medical condition that would make prednisone (corticosteroid) use contraindicated~* Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone bid~* Treatment with more than one chemotherapy agent for prostate cancer~* Prior systemic radiotherapy and hemibody external radiotherapy~* History of pituitary or adrenal dysfunction~* Chronic conditions associated with non-malignant abnormal bone growth (e.g., confirmed Paget's disease of bone)~* Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy~* History of seizures (taking/not taking anticonvulsants), arteriovenous malformation in the brain, head trauma with loss of consciousness~* Central nervous system (CNS) metastases

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Xofigo, BAY88-8223) (Type: EXPERIMENTAL): None
- Radium-223 with abiraterone&prednisone (Type: EXPERIMENTAL): None
- Radium-223 with enzalutamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).